Resource Summary Report

Generated by RRID on Aug 4, 2026

Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated

RRID:AB_330403
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3771, RRID:AB_330403

Antibody Information

URL: http://antibodyregistry.org/AB_330403

Proper Citation: Cell Signaling Technology Cat# 3771, RRID:AB_330403

Target Antigen: Jak2, phospho (Tyr1007 / Tyr1008)

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10889738, AB_10891428, AB_330403, AB_330405.

Antibody Name: Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated

Description: This unknown targets Jak2, phospho (Tyr1007 / Tyr1008)

Target Organism: rat, mouse, human

Antibody ID: AB_330403

Vendor: Cell Signaling Technology

Catalog Number: 3771

Record Creation Time: 20250820T045450+0000

Record Last Update: 20250820T201630+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated.

No alerts have been found for Anti-Jak2, phospho (Tyr1007 / Tyr1008) Antibody, Unconjugated.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Han J, et al. (2025) FGL2-induced metabolic dysregulation in enteric neural crest cells provides insight into Hirschsprung disease pathogenesis. iScience, 28(9), 113423.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. Cell reports. Medicine, 6(11), 102448.

Wang Z, et al. (2025) Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease. Cell metabolism, 37(5), 1089.

Sun B, et al. (2025) A novel compound DBZ alleviates chronic inflammatory pain and anxiety-like behaviors by targeting the JAK2-STAT3 signaling pathway. The Journal of biological chemistry, 301(7), 110223.

Ghosh C, et al. (2024) Type I gamma phosphatidylinositol phosphate 5-kinase i5 controls cell sensitivity to interferon. Developmental cell.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell, 187(9), 2288.

Zhang J, et al. (2024) Influenza A virus infection activates STAT3 to enhance SREBP2 expression, cholesterol biosynthesis, and virus replication. iScience, 27(8), 110424.

Xie Y, et al. (2024) Deciphering the composition and key driver genes of breast invasive micropapillary carcinoma by multi-omics analysis. iScience, 27(11), 111178.

Han L, et al. (2024) AhR-STAT3-HO-1/COX-2 signalling pathway may restrict ferroptosis and improve hMSC accumulation and efficacy in mouse liver. British journal of pharmacology, 181(1), 125.

Cao J, et al. (2024) Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury. Neural regeneration research, 19(11), 2499.

Manoharan J, et al. (2024) Tissue factor binds to and inhibits interferon-? receptor 1 signaling. Immunity, 57(1), 68.

Du T, et al. (2024) Chronic sleep deprivation disturbs energy balance modulated by suprachiasmatic nucleus efferents in mice. BMC biology, 22(1), 296.

Milara J, et al. (2024) Targeting IL-11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis. British journal of pharmacology, 181(16), 2991.

Cao W, et al. (2023) Exosomes derived from platelet-rich plasma promote diabetic wound healing via the JAK2/STAT3 pathway. iScience, 26(11), 108236.

Ye F, et al. (2023) TGF? Antagonizes IFN?-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Cancer research, 83(13), 2262.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine, 4(10), 101214.

Shen X, et al. (2023) cGAS Mediates Inflammation by Polarizing Macrophages to M1 Phenotype via the mTORC1 Pathway. Journal of immunology (Baltimore, Md. : 1950), 210(8), 1098.

Fang Z, et al. (2023) Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nature communications, 14(1), 7725.

Song Z, et al. (2023) Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma. Biochemical pharmacology, 213, 115612.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(5), 943.